SCHEMBL18148199

SCHEMBL18148199

CNC(=O)COc1c(NS(=O)(=O)c2ccc[nH]2)cc2c(ncn2C)c1F

nearest known ligand 0.38

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ACLY P53396 1/20 0.38
LMNA P02545 1/20 0.35
NOTUM Q6P988 2/20 0.33
MAP2K2 P36507 2/20 0.33
MAP2K1 Q02750 2/20 0.33
RECQL P46063 2/20 0.33
ABCB11 O95342 1/20 0.33
NQO2 P16083 1/20 0.33
NPC1 O15118 1/20 0.33
RAB9A P51151 1/20 0.33
PKM P14618 1/20 0.33
SMC2 O95347 1/20 0.32
EGFR P00533 1/20 0.32
CSNK2A2 P19784 1/20 0.32
SMC1A Q14683 1/20 0.32
AAK1 Q2M2I8 1/20 0.32
Q6ZSR9 Q6ZSR9 1/20 0.32
BMP2K Q9NSY1 1/20 0.32
MEN1 O00255 1/20 0.32
KMT2A Q03164 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL18147976 0.88 LMNA (0.36) LMNAMAP2K2MAP2K1RECQLABCB11
SCHEMBL18148024 0.84 LMNA (0.35) LMNAMAP2K2MAP2K1RECQLABCB11
SCHEMBL18148033 0.80 HDAC1 (0.36) LMNARECQLMEN1KMT2AALDH1A1
SCHEMBL18148044 0.78 LMNA (0.37) LMNAMAP2K2MAP2K1RECQLABCB11
SCHEMBL18148041 0.78 LMNA (0.37) LMNAMAP2K2MAP2K1RECQLABCB11
SCHEMBL18163759 0.77 CNKSR1 (0.38) LMNAMAP2K2MAP2K1RECQLABCB11
SCHEMBL18147950 0.75 LMNA (0.36) LMNARECQLMEN1KMT2AALDH1A1
SCHEMBL18148031 0.74 TSHR (0.35) LMNARAB9AKMT2AALDH1A1SMN1; SMN2
SCHEMBL18147963 0.73 PIK3CA (0.40) LMNARAB9AALDH1A1
SCHEMBL18148020 0.70 ALDH1A1 (0.42) LMNAPKMMEN1KMT2AALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-10227356-B2 Compounds, compositions and methods for inhibiting CNKSR1 PHUSIS THERAPEUTICS, INC. (US) 2019-03-12 US disclosed
US-10227356-B2 Compounds, compositions and methods for inhibiting CNKSR1 PHUSIS THERAPEUTICS, INC. (US) 2019-03-12 US disclosed
US-20160304533-A1 COMPOUNDS, COMPOSITIONS AND METHODS FOR INHIBITING CNKSR1 PHUSIS THERAPEUTICS, INC. (US) 2016-10-20 US disclosed
US-20160304533-A1 COMPOUNDS, COMPOSITIONS AND METHODS FOR INHIBITING CNKSR1 PHUSIS THERAPEUTICS, INC. (US) 2016-10-20 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-10227356-B2 Compounds, compositions and methods for inhibiting CNKSR1 CNKSR1, CAMKK1, CNR1 ACLY 1842/4885LMNA 1703/4885NOTUM 3960/4885
US-20160304533-A1 COMPOUNDS, COMPOSITIONS AND METHODS FOR INHIBITING CNKSR1 CNKSR1, CAMKK1, CNR1 ACLY 1842/4885LMNA 1703/4885NOTUM 3960/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.